These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15615459)

  • 1. [Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
    Janić D; Dokmanović L; Jovanović N; Skorić D; Lazić J
    Srp Arh Celok Lek; 2004 Oct; 132 Suppl 1():17-22. PubMed ID: 15615459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
    Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
    Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
    Karachunskiĭ AI; Miakova NV; Rumiantseva IuV; Timakov AM; Makhortykh TZh; Fechina LG; Shamardina AV; Dudkin SA; Lebedev VV; Varfolomeeva SR; Timofeeva VN; Herold R; Stakelberg A; Henze G; Rumiantsev AG
    Ter Arkh; 2007; 79(7):19-26. PubMed ID: 17802785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
    Starý J; Gajdos P; Blazek B; Ptoszková H; Mihál V; Pospísilová D; Hrstková H; Dembická D; Kopecná L; Slavík Z; Hak J; Procházková D; Zahálka F; Cerná Z; Jabali Y; Timr P; Vávra V; Mydlil J; Hrusák O; Trka J
    Cas Lek Cesk; 2003; 142(7):404-9. PubMed ID: 14515443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting.
    Malhotra P; Varma S; Varma N; Kumari S; Das R; Jain S; Ahluwalia J; Mahi S; Sharma SC; Radhika S
    Leuk Lymphoma; 2007 Jun; 48(6):1173-8. PubMed ID: 17577781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group].
    Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Armata J; Balcerska A; Balwierz W; Bubala H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Łukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sonta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E
    Med Wieku Rozwoj; 2000; 4(1 Suppl 2):43-8. PubMed ID: 12021461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy.
    Malhotra P; Kapoor G; Jain S; Garg B
    Indian Pediatr; 2018 Oct; 55(10):877-879. PubMed ID: 29941701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
    Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
    Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
    Glodkowska E; Bialas A; Jackowska T
    Med Wieku Rozwoj; 2007; 11(2 Pt 1):153-8. PubMed ID: 17625285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study.
    Dujua AC; Hernandez FG
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):e116-e123. PubMed ID: 28085747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
    Aricò M; Conter V; Valsecchi MG; Rizzari C; Boccalatte MF; Barisone E; Messina C; De Rossi G; Lo Nigro L; Pession A; Locatelli F; Micalizzi C; Basso G
    Haematologica; 2005 Sep; 90(9):1186-91. PubMed ID: 16154841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
    Holownia A; Trofimiuk E; Krawczuk-Rybak M; Jakubow P; Kaliszewski J; Muszynska-Roslan K; Braszko JJ
    Acta Haematol; 2004; 112(4):222-4. PubMed ID: 15564737
    [No Abstract]   [Full Text] [Related]  

  • 17. [Reults of treatment with protocols BFM 90 and BFM 95].
    Sakić M; Berbić-Fazlagić J
    Med Arh; 2006; 60(6):369-72. PubMed ID: 17297851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
    Kwiecińska K; Balwierz W; Moryl-Bujakowska A; Wachowiak J; Derwich K; Matysiak M; Pawelec K; Chybicka A; Dobaczewski G; Kowalczyk JR; Wiśniewska-Slusarz H; Sońta-Jakimczyk D; Szczepański T; Tomaszewska R; Wysocki M; Styczyński J; Balcerska A; Płoszyńska A
    Przegl Lek; 2010; 67(6):350-4. PubMed ID: 21344760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol.
    Moriya K; Imamura T; Katayama S; Kaino A; Okamoto K; Yokoyama N; Uemura S; Kitazawa H; Sekimizu M; Hiramatsu H; Usami I; Ishida H; Hasegawa D; Hama A; Moriya-Saito A; Sato A; Sasahara Y; Suenobu S; Horibe K; Hara J;
    Br J Haematol; 2022 Mar; 196(5):1257-1261. PubMed ID: 34879431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.